Roth Capital Starts Recro Pharma (REPH) at Buy
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Roth Capital initiated coverage on Recro Pharma (NASDAQ: REPH) with a Buy rating and a price target of $24.00.
Shares of Recro Pharma closed at $9.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham & Company Starts AMAG Pharmaceuticals (AMAG) at Buy
- AK Steel (AKS) PT, Estimates Raised at Jefferies
- RBC Capital Cuts Price Target on Pentair (PNR) to $66 Following 3Q Report
Create E-mail Alert Related CategoriesNew Coverage
Related EntitiesRoth Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!